Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
Pharmaceutics · 13.05.2023 · 15 (5) · 1488
DOI: 10.3390/pharmaceutics15051488 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 13.05.2023. Verfasst von Xiaoxuan Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Mel…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NHMRC, Cystic Fibrosis Australia.
Abstract (Originalsprache)
Pulmonary drug delivery has long been used for local and systemic administration of different medications used in acute and chronic respiratory diseases. Certain lung diseases, such as cystic fibrosis, rely heavily on chronic treatments, including targeted lung delivery. Pulmonary drug delivery possesses various physiological advantages compared to other delivery methods and is also convenient for the patient to use. However, the formulation of dry powder for pulmonary delivery proves challenging due to aerodynamic restrictions and the lower tolerance of the lung. The aim of this review is to provide an overview of the respiratory tract structure in patients with cystic fibrosis, including during acute and chronic lung infections and exacerbations. Furthermore, this review discusses the advantages of targeted lung delivery, including the physicochemical properties of dry powder and factors affecting clinical efficacy. Current inhalable drug treatments and drugs currently under development will also be discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.
ORCID-Profile: Felisa Reyes-Ortega, Elena K Schneider-Futschik
Förderung
- National Health and Medical Research Council
- NHMRC
- Cystic Fibrosis Australia
Zitieren
APA
Han, X., Li, D., Reyes-Ortega, F., & Schneider-Futschik, E. K. (2023). Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis. Pharmaceutics, 15(5), 1488. https://doi.org/10.3390/pharmaceutics15051488
Vancouver
Han X, Li D, Reyes-Ortega F, Schneider-Futschik EK. Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis. Pharmaceutics. 2023;15(5):1488. doi:10.3390/pharmaceutics15051488
BibTeX
@article{Han2023,
author = {Han, Xiaoxuan and Li, Danni and Reyes-Ortega, Felisa and Schneider-Futschik, Elena K},
title = {Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {5},
pages = {1488},
doi = {10.3390/pharmaceutics15051488}
}
EUVIMED